Overview

Adjunct Episcleral Brachytherapy for PCV

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Salutaris Medical Devices, Inc.

Treatments:

Aflibercept